D
elayed graft function (DGF), defined by the Organ Procurement and Transplantation Network (OPTN) and the United Network for Organ Sharing (UNOS) as dialysis in the first week of kidney transplant, is an early complication that occurs in nearly a quarter of all deceased-donor kidneys. 1 Studies have linked DGF with increased costs, higher rates of acute and chronic rejection, and worse allograft and patient survivals. [2] [3] [4] In the setting of these as well as recent clinical trial data, 5, 6 the Food and Drug Administration (FDA) endorsed the concept of DGF as a clinically relevant registration endpoint for drug development trials in kidney transplantation. 7 Notwithstanding, the relationship between DGF and later outcomes is not absolute, and many recipients that require temporary dialysis within the first several days of transplant eventually achieve acceptable baseline allograft function. As a clear example of this disconnect, kidneys from donors with circulatory determination of death (DCD) experience DGF at higher rates (over 40%) than standard-criteria kidneys (23%), but subsequent outcomes are comparable. 1, 8, 9 Ischemia-reperfusion injury (IRI) resulting in acute kidney injury (AKI) of varying reversibility is the most common reason allografts fail to function immediately after implantation. In nontransplant settings, both severity and duration of AKI associate with mortality, 10 and AKI severity has been linked with chronic kidney disease progression. 11, 12 Although dialysis-defined DGF can be considered a severe form of AKI, the definition lacks granularity in terms of both severity and duration of allograft injury at transplantation. Furthermore, some degree of subjectivity is unavoidable with dialysis-defined DGF given that thresholds for dialysis decisions can differ between physicians and between centers in the early posttransplant period. 13 Recognizing the subjective nature of some dialysis decisions, the FDA called for "better disease definitions in short-term appraisals" regarding DGF. 7 Even before this call to action, investigators used many different DGF definitions to describe the clinical experiences and outcomes at a number of centers, 14 and multiple investigators (including authors of the current work) have considered the concept of "slow graft function" (SGF) to describe varying serum creatinine (SCr) concentrations in peritransplant recipients that do not require dialysis. 13, [15] [16] [17] [18] [19] Evaluating early posttransplant SCr reductions in the absence of dialysis avoids confusion because of intentional creatinine removal but still ignores variable center thresholds for early dialysis indications. A diagnostic algorithm for peritransplant graft function that incorporates all of these concepts relative to both severity and duration of allograft injury would be of tremendous benefit for kidney transplant trials.
Members of our research group previously proposed redefining DGF by combining the need for more than 1 dialysis session or a creatinine reduction ratio (CRR) less than 25% "within the first 48 h posttransplant." 14 We therefore conducted the current multicenter study to primarily test the validity of this DGF definition and secondarily determine associations between frequently described definitions for SGF in the immediate posttransplant period with the following 12-month outcomes: estimated glomerular filtration rate (eGFR), death-censored graft failure, acute rejection and mortality. We hypothesized that 12-month eGFR would differ between recipients with versus without DGF by the UNOS definition, but that other DGF and SGF "phenotypes" would also associate with 12-month eGFR after multivariable adjustment for important donor, transplant and recipient characteristics.
MATERIALS AND METHODS

Study Cohort
For this observational cohort study, we collected data from deceased kidney donors whose surrogates had consented to research at 5 organ procurement organizations (OPOs) between April 2010 and December 2013. We prospectively followed up recipients of these donor kidneys at 5 transplant centers. The scientific review committees for participating OPOs and institutional review boards for the participating centers approved the protocol. We excluded recipients younger than 16 years and recipients of dual or en-bloc kidneys, kidneys from donors younger than 5 years, and multiorgan transplants other than simultaneous pancreaskidneys. One recipient of an allograft that immediately thrombosed and was removed 12 hours after transplantation was also excluded.
Data Abstraction
This study also used data from the OPTN data system, which includes information on all donor, waitlisted candidates, and transplant recipients in the United States, submitted by the members of the OPTN, as described elsewhere. The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the OPTN contractor (currently UNOS). Donor variables were abstracted from OPO charts. We calculated the Kidney Donor Risk Index as described by Rao et al. 20, 21 We converted the Kidney Donor Risk Index, as per convention, 20 to obtain the Kidney Donor Profile Index (KDPI) relative to all US deceased donors in 2010. Trained study coordinators reviewed all available medical records for recipient characteristics, treatments, and outcomes. Daily SCr, urine output (UOP), and dialysis episodes were abstracted from initial transplant hospitalization records. After discharge, outpatient records were reviewed for subsequent dialysis needs and other data. The principal investigator at each site confirmed all posttransplant dialysis episodes and indications by reviewing medical records. Coordinators and analysts at the coordinating center (Yale School of Medicine) performed extensive data quality checks and validations.
Exposure Variables
We categorized recipients as having DGF, SGF, or "immediate graft function" (IGF) according to several literaturebased definitions. We considered the following SCr criteria for defining SGF: SCr on postoperative day 5 (POD5Cr, cutoff >3 mg/dL), 13 SCr on POD7 (POD7Cr, cutoff ≥2.5 mg/ dL), 22, 23 CRR in the first 24 hours (CRR24h; [POD0 SCr-POD1 SCr)/POD0 SCr], cutoff <25%), 24 CRR in the first 48 hours (CRR48h, cutoff <25%), 14 CRR between POD1 and POD2 (CRR2, cutoff <30%), 17 CRR over 3 consecutive days within the first week (CRR3, cutoff <10%/day), 25 CRR between POD0 and POD7 (CRR7, cutoff <70%), 18 and number of days to reach creatinine clearance 10 mL/min or greater (CrCl10, cutoff >6 days, estimated by CockroftGault equation: (sex Â [140 − age in years]/[SCr in mg/dL] Â [kg/72]), where sex = 1 for male, 0.85 for female; ignoring SCr on days after dialysis posttransplant). 15 We calculated average hourly UOP from transplant to the morning of POD1 (UOP1) and from the morning of POD1 to 2 (UOP2). For both assessments, we used less than 42 mL/h to approximate less than 1000 mL/24 h as the cutoff. 26, 27 For each definition, recipients not dialyzed in the first week (ie, no UNOS-DGF) and not found to have SGF were categorized as having IGF.
For recipients dialyzed at least once in the first week (ie, those with UNOS-DGF), we defined dialysis duration as the number of days from transplant to the last dialysis session.
We characterized dialysis timing and number based on whether recipients with only 1 session received it by POD1 (versus after POD1). Thus, we defined dialysis number as: −1, not dialyzed; 0, dialyzed once on POD1; 1, dialyzed once after POD1; 2, dialyzed twice; and 3, dialyzed 3 times or more. To analyze the previously proposed DGF definition, we categorized recipients with "DGF48h" if they had CRR48h less than 25% or underwent more than 1 dialysis session within the first week.
Outcome Variables
We calculated eGFR from clinical SCr measurements at specified timepoints via the Chronic Kidney Disease Epidemiology Collaboration equation. 28 No center routinely performed protocol biopsies during the study period. Acute rejection was defined according to the treating transplant physician (ie, biopsy-confirmed or clinically treated without biopsy). We defined death-censored graft failure as resumption (or initiation for preemptive transplants) of maintenance dialysis or retransplantation. Primary nonfunction was defined as continued dialysis beyond 90 days after transplant and was counted as death-censored graft failure. We imputed eGFR as 10 mL/min per 1.73 m 2 for recipients after deathcensored graft failure. In the event of recipient death with a functioning allograft, we carried forward the last available SCr to calculate eGFR.
Statistical Analysis
Descriptive statistics were reported as mean (SD or SE of the mean) or median (interquartile range) for continuous variables and as frequency (percentage) for categorical variables. We compared donor and recipient characteristics and 12-month outcomes (eGFR as the primary outcome along with the following secondary outcomes: acute rejection, death-censored graft failure and patient death) by UNOS-DGF status using Wilcoxon rank-sum tests and Pearson χ 2 tests. During analysis planning, we anticipated a minimal detectable difference in 12-month eGFR (at 80% power and alpha = 0.05) of 5 mL/min per 1.73 m 2 . These estimates indicated our final analysis was capable of detecting a 5.4 mL/min per 1.73 m 2 difference between UNOS-DGF groups. We also calculated Pearson correlation coefficients between POD5Cr (log 2 -transformed), POD7Cr (log 2 -transformed), CRR24h, CRR48h, CRR2, CRR7, UOP1 (log 2 -transformed), UOP2 (log 2 -transformed), and 12-month eGFR. We then compared (via Wilcoxon ranksum) 12-month eGFR by DGF48h status (capable of detecting a difference of 5.3 mL/min per 1.73 m 2 at 80% power and alpha = 0.05). The various 3-level IGF-SGF-DGF criteria were evaluated by linear models using planned contrasts for pair-wise comparisons for 12-month eGFR differences between groups (without statistical adjustment for multiple comparisons).
We fit multivariable regression models to estimate the relationship between each clinical scenario (UNOS-DGF, DGF48h, and each IGF-SGF-DGF definition described above) and 12-month eGFR (continuous) and 12-month eGFR <30 mL/min per 1.72 m 2 (vs ≥30 mL/min per 1.72 m 2 , a dichotomous outcome). To account for the possible correlation of outcomes between recipients of kidneys from the same donor, we fit linear mixed regression models with a donor-specific random intercept for the continuous outcome and modified Poisson regression models to estimate relative risk for the dichotomous outcome. For multivariable adjustments, we added the following donor variables: age (years), black race, height (cm), weight (kg), hypertension, diabetes, stroke as cause of death, DCD status, and terminal SCr (mg/dL); and we then added the following transplant/recipient variables: cold ischemia time (hours), number of human leukocyte antigen mismatches, age (years), black race, gender, previous kidney transplant, diabetes as the cause of end stage renal disease, body mass index (kg/m 2 ), dialysis vintage (months) before transplant, and panel reactive antibody (percent).
We used the Akaike information criterion (AIC) to compare between models to predict 12-month eGFR. The AIC is useful for comparing different types of models because it does not require the models to be nested (the smaller the AIC, the better fit that model provides relative to the others). Given the nested relationship between each of the IGF-SGF-DGF models and the UNOS-DGF model, we also compared each against UNOS-DGF for predicting 12-month eGFR with multivariable adjustment using likelihood-ratio tests. We generated penalized basis spline curves fit with 10 knots and automatically selected smoothing parameters to visualize the relationship between each continuous predictor and 12-month eGFR. We calculated the R 2 value for each of these curves. For the dichotomous outcome, we performed receiver-operating characteristic curve analyses to determine the area under the curve (AUC) for each model.
Sensitivity analyses were performed after excluding graft failures or deaths (as opposed to imputing eGFR). With additional follow-up, we also analyzed 24-month eGFR as a secondary outcome. We performed additional linear regression analyses to test for possible interactions on 12-month eGFR for UNOS-DGF and DGF48h based on kidney quality (KDPI >85 and DCD status) and transplant center. We used SAS 9.3 statistical software for Windows (SAS Institute, Cary, NC) and applied a 2-sided significance level of 0.05 for all tests and confidence intervals.
RESULTS
Cohort Description
A flow diagram for study exclusions is shown in Figure 1 . Of 560 transplants from 485 donors, 215 (38%) had UNOS-DGF. 330 (59%) recipients had DGF48h (192 with CRR48h <25% only, 33 with >1 dialysis session only, 105 with both CRR48h <25% and >1 dialysis session). By 12-month, 66 (12%) recipients experienced acute rejection, 23 (4%) had death-censored graft failure (18 [78%] of which classified as primary nonfunction), 14 (3%) had died, and 11 (2%) were lost to follow-up. Median 12-month eGFR was 54 (42-69) mL/min per 1.73 m As shown in Tables 1A and 1B, only 2 of 38 preemptive recipients experienced UNOS-DGF. Otherwise, those with UNOS-DGF tended to have longer dialysis vintage and were more often black race. Kidneys with UNOS-DGF tended to come from donors that were older, more frequently DCD, and had higher terminal SCr and KDPI values. For the 45 (21%) recipients with UNOS-DGF dialyzed only once by POD1, hyperkalemia was the most common indication (37 cases). For the 32 (15%) recipients with UNOS-DGF dialyzed once but after POD1, uremia was the most common indication (28 cases). Uremia was also the most common indication for recipients dialyzed more than once (>80% for uremia).
Associations With 12-Month Graft Function
As shown in Table 2 , recipients with UNOS-DGF had significantly lower 12-month eGFR than those without UNOS-DGF with a difference (95% confidence interval [95% CI]) of −11.9 (−15.6 to −8.2) mL/min per 1.73 m 2 . Results were similar for DGF48h with a difference of −13.2 (−16.9 to −9.5) mL/min per 1.73 m 2 compared with recipients without DGF48h. For eGFR less than 30 mL/min per 1.73 m 2 at 12 months, sensitivity and specificity were 58% and 64%, respectively, for UNOS-DGF; 81% and 44%, respectively for DGF48h. Adjusted relative risk (95% CI) for 12-month eGFR less than 30 mL/min per 1.73 m 2 with UNOS-DGF and DGF48h was 1.9 (1.2-3.1) and 2.1 (1.1-3.7), respectively. The AUC (95% CI) for predicting 12-month eGFR less than 30 mL/min per 1.73 m Continuous values for POD5Cr, POD7Cr, CRR24h, CRR48h, CRR2, CRR3, CRR7, UOP1, and UOP2 were significantly correlated with 12-month eGFR with Pearson coefficients of −0.37, −0.43, 0.25, 0.32, 0.28, −0.10, 0.38, 0.31, and 0.28, respectively (all P values <0.0001). Using the typical literature-based cutoff and as shown in Table 3 Table 4 shows adjusted mean (SE) 12-month eGFR by the different IGF-SGF-DGF cutoffs for each of these variables and UNOS-DGF. Only POD5Cr and CRR2 demonstrated significant separation in adjusted mean 12-month eGFR between IGF-SGF-DGF groups (ie, each group was statistically different from the others via pairwise comparisons). However, the AIC was smallest for POD7Cr, indicating the fully adjusted model that incorporates a SCr cutoff of 2.5 mg/dL on POD7 for recipients that do not require dialysis may be the best overall predictor of 12-month eGFR relative to all other models studied. Table 5 provides additional unadjusted and adjusted linear regression results for 12-month eGFR utilizing continuous SCr and UOP-based variables (along with dialysis number and duration) rather than typical cutoffs. The AIC results again point to POD7Cr as the strongest predictor. Figure 2 shows spline curves for 12-month eGFR versus POD7Cr and dialysis duration with resulting R 2 values (spline curves for the other continuous predictors included as Figures S2-S4 , SDC, http://links.lww.com/TP/B326). Table 2 shows acute rejection, death-censored graft failure and recipient death at 12 months separated by UNOS-DGF and DGF48h status. Although neither definition was associated with acute rejection or death, both were associated with 12-month death-censored graft failure with unadjusted relative risks of 4.5 (1.8, 11.3) for UNOS-DGF and 3.3 (1.1, 9.5) for DGF48h. However, only UNOS-DGF remained independently associated with an adjusted relative risk for 12-month death-censored graft failure of 4.7 (1.6, Table 3 provides mean (SD) 6-month and 24-month eGFR values in addition to mean 12-month eGFR separated by the different SCr and UOP-based criteria. Figure 3 depicts mean 6-, 12-, and 24-month eGFR according to dialysis number and duration.
Secondary Outcomes and Sensitivity Analyses
As shown in Table 2 , sensitivity analyses did not substantially alter the primary 12-month results. However, excluding the 37 recipients with graft failure or death within 12 months attenuated the inverse association between UNOS-DGF and 12-month eGFR slightly more than between DGF48h and 12-month eGFR.
There was no apparent effect modification between UNOS-DGF or DGF48h and kidney quality (KDPI >85 or DCD status, all interaction P values >0.05) with 12-month eGFR. There was also no discernible effect modification between transplant center and DGF48h on 12-month eGFR (P = 0.59). The deleterious effect of UNOS-DGF on 12-month eGFR was potentially more severe (interaction P values <0.05) at 2 of the participating centers with linear regression coefficients for UNOS-DGF ranging from −2.3 to −15.3 among all 5 centers.
DISCUSSION
Using prospective, multicenter cohort data for deceaseddonor kidney transplant recipients in the modern era, we have shown that UNOS-defined DGF is associated with a reduced eGFR at 12 months by approximately 7 mL/min per 1.73 m 2 after adjusting for multiple donor, transplant, and recipient factors. We found a previously proposed but not validated DGF definition (based on the combination of impaired creatinine reduction in the first 48 hours or >1 dialysis session in the first week) 14 resulted in 12-month allograft outcomes that were generally similar to UNOS-DGF. We also found several SCr and UOP-based criteria reported in the literature to describe SGF in the absence of dialysis are associated with 12-month eGFR. Two criteria (POD5Cr and CRR2) demonstrated significant separation in adjusted 12-month eGFR between all 3 IGF-SGF-DGF groups; however, POD7Cr demonstrated the strongest overall association with 12-month eGFR.
There continues to be much interest in appraising peritransplant function. Mallon et al 29 recently reported comparable predictive power, in terms of 12-month eGFR and long-term graft survival, for 10 DGF definitions at a single center in the United Kingdom. The authors concluded by recommending universal adoption of the UNOS-DGF definition given the arguable lack of superiority for any other definition evaluated, its descriptive simplicity, and its applicability regarding both length of stay and retrospective analyses. We UNOS-DGF is any dialysis in the first posttransplant week. DGF48h is delayed graft function defined as a serum creatinine reduction of <25% in the first 48 h or >1 dialysis session in the first posttransplant week. Values are mean ± standard deviation, n (%), or measure of association (95% confidence interval) as indicated.
would offer (what we believe also reflects FDA recommendations) that the primary motivation to improve peritransplant functional assessment should be the development of a reliable early surrogate outcome for use in clinical trials, with less emphasis on retrospective studies.
Future trials to reduce in-hospital dialysis after transplant could be worthwhile in moderating costs. However, with meaningful improvements in long-term allograft function and longevity as the primary goal, we could expect even greater and more durable savings in terms of the economics (20) 51 (20) 66 (25) 58 (25) 66 (25) 60 (24) Postoperative day 7
63 (20) 48 (20) 66 (24) 54 (25) 67 (24) 56 (25) Creatinine reduction ratio Over first 24 h 68 (19) 55 (20) 70 (26) 59 (24) 70 (25) 61 (24) Over first 48 h 63 (20) 52 (21) 65 (25) 59 (24) 66 (25) 60 (24) Postoperative days 1 to 2 65 (20) 54 (21) 67 (26) 59 (24) 69 (26) 60 (24) Over 3 consecutive days in first week 61 (21) 52 (19) 63 (25) 59 (25) 65 (25) 60 (24) Postoperative days 0 to 7 64 (20) 53 (20) 66 (25) 58 (24) 66 (26) 60 (24) Days to reach creatinine clearance >10 mL/min 59 (21) 44 (17) 62 (25) 63 (32) 64 (25) 63 (32) Urine output Postoperative day 1 60 (21) 45 (17) 63 (25) 52 (22) 64 (25) 55 ( (20) 55 (26) 63 (25) 57 (24) 64 (25) 62 ( , that result from categorizing all 345 recipients that did not require dialysis in the first 7 days after transplant as having either IGF or SGF according to each literature-based cutoff as described below. Mean (SD) eGFR at 6, 12, and 24 months for all 345 recipients was 59 (21), 60 (22) , and 62 (25) mL/min per 1.73 m 2 , respectively. Postoperative day 5 serum creatinine (POD5Cr: IGF <3 mg/dL, n = 197; SGF ≥3 mg/dL, n = 148), postoperative day 7 serum creatinine (POD7Cr: IGF <2.5 mg/dL, n = 240; SGF ≥2.5 mg/dL, n = 10), creatinine reduction ratio over the first 24 h (CRR24h: IGF ≥0.25, n = 93; SGF <0.25, n = 252), creatinine reduction ratio over the first 48 h (CRR48h: IGF ≥0.25, n = 204; SGF <0.25, n = 141), creatinine reduction ratio from postoperative days 1 to 2 (CRR2: IGF ≥0.3, n = 141; SGF <0.3, n = 204), creatinine reduction ratio over 3 consecutive days in the first week (CRR3: IGF ≥0.1, n = 262; SGF <0.1, n = 83), creatinine reduction ratio from postoperative day 0 to 7 (CRR7: IGF ≥0.7, n = 184; SGF <0.7, n = 161), days to reach a creatinine clearance by Cockroft-Gault equation ≥10 mL/min (CrCl10: IGF ≤6 days, n = 331; SGF >6 days, n = 14), average hourly urine output from transplant to the morning of postoperative day 1 (UOP1: IGF ≥42 mL/h, n = 307; SGF <42 mL/h, n = 30), average hourly urine output from the morning of postoperative day 1 to 2 (UOP2: IGF ≥42 mL/h, n = 302; SGF <42 mL/h, n = 42). c Indicates which (if any) IGF-SGF-DGF group is significantly different from the other 2 groups in terms of 12-month eGFR via pair-wise comparisons for that particular row. Predicted mean (standard error) 12-month estimated glomerular filtration rate (eGFR) in mL/min per 1.73 m 2 via linear regression models adjusted for the following donor variables: age, circulatory death (rather than brain death), black race, hypertension, diabetes, height, weight, stroke as cause of death, and terminal serum creatinine; and the following transplant/recipient variables: cold ischemia time, age, black race, sex, previous kidney transplant, diabetes as the cause of end stage renal disease, number of human leukocyte antigen mismatches, body mass index, duration (vintage) of dialysis before transplant, and percent panel reactive antibody. IGF and SGF were defined according to the literature-based cutoffs described below. DGF was defined as any dialysis in the first week after transplant according to the United Network for Organ Sharing definition. Postoperative day 5 serum creatinine (POD5Cr: IGF <3 mg/dL, n = 197; SGF ≥3 mg/dL, n = 148), postoperative day 7 serum creatinine (POD7Cr: IGF <2.5 mg/dL, n = 240; SGF ≥2.5 mg/dL, n = 10), creatinine reduction ratio over the first 24 h (CRR24h: IGF ≥0.25, n = 93; SGF <0.25, n = 252), creatinine reduction ratio over the first 48 h (CRR48h: IGF ≥0.25, n = 204; SGF <0.25, n = 141), creatinine reduction ratio from postoperative days 1 to 2 (CRR2: IGF ≥0.3, n = 141; SGF <0.3, n = 204), creatinine reduction ratio over 3 consecutive days in the first week (CRR3: IGF ≥0.1, n = 262; SGF <0.1, n = 83), creatinine reduction ratio from postoperative day 0 to 7 (CRR7: IGF ≥0.7, n = 184; SGF <0.7, n = 161), days to reach a creatinine clearance by Cockroft-Gault equation ≥10 mL/min (CrCl10: IGF ≤6 days, n = 331; SGF >6 days, n = 14), average hourly urine output from transplant to the morning of postoperative day 1 (UOP1: IGF ≥42 mL/h, n = 307; SGF <42 mL/h, n = 30), average hourly urine output from the morning of postoperative days 1 to 2 (UOP2: IGF ≥42 mL/h, n = 302; SGF <42 mL/h, n = 42).
of chronic kidney disease care, need for retransplantation, and recipient work productivity. As an example of the potential impact of using another definition, data from the current study show that 59% of recipients without UNOS-DGF would be correctly reclassified as high risk (14% with UNOS-DGF correctly reclassified as low risk) for poor 12-month allograft function (eGFR <30 mL/min per 1.73 m 2 ) if the early outcome were instead defined by DGF48h. This alternate definition is clearly not perfect, however, and could even be deleterious to future trial design given tradeoffs between improved sensitivity and worse specificity for 12-month eGFR <30 mL/min per 1.73 m 2 compared with the UNOS-DGF definition. In terms of other dialysis-based definitions, we noted a significant stepwise decrease in 12-month eGFR according to dialysis number, but we were somewhat surprised by numerically (though not significantly) better eGFRs for dialysis durations between 8 and 14 days compared with durations between 1 and 7 days. Most importantly, these analyses highlight the limitations of current DGF definitions based on SCr, UOP, and/or dialysis.
The current study also demonstrates an important consideration about allograft functional assessments both peritransplant and during follow-up-that is, our continued reliance on SCr itself. Serum creatinine does not accurately reflect GFR in the nonsteady state, which is a rule in peritransplant and a common occurrence during follow-up. Numerous conditions other than GFR also affect SCr, including muscle mass and medications. In addition, because dialysis removes creatinine, pretransplant dialysis timing can greatly affect CRRs, which we observed while investigating apparent outliers in this cohort. This issue leads some to ignore SCr on postdialysis days (eg, CrCl10 in the current study based on work by Giral-Classe et al 15 ). Furthermore, because SCr is used to estimate GFR, the fact that POD7Cr had the strongest association with 12-month eGFR is not too surprising and is consistent with the SCr data (particularly POD7 and POD10) reported by Mallon et al. 29 In terms of allograft survival, a recently proposed tool to predict 5-year survival on POD7 incorporated discharge eGFR with dialysis-defined DGF along with multiple other variables. 30 We would anticipate that later SCr and/or eGFR values would associate with subsequent allograft function and survival even better than POD7Cr. Kaplan et al showed each 1 mg/dL increase in SCr during the first year of follow-up was associated with over 2-fold risk for allograft failure, 31 but they argued that the change in SCr had poor predictive value with an AUC for allograft failure of only 0.627. Although Smail and colleagues 32 noted worse death-censored allograft survival in recipients of expanded-criteria kidneys with SGF (which they defined as CRR <20% in the first 24 hours) but no allograft survival difference based on dialysis-defined DGF, they found a greater than 30% decline in eGFR from month 1 to month 12 after transplant was associated with worse allograft survival (hazard ratio of 2.2, P = 0.02). Most recently, Clayton et al 33 also found that a 30% or more decline in eGFR (though from year 1 to 3 after transplant) was associated with over 5-fold risk of subsequent death-censored graft failure. As these prior reports infer, rather than relying on predictors that only become available years later, additional prospective studies are needed to discover effective, mechanistic peritransplant predictors of long-term allograft survival. We believe more studies are needed to determine whether measuring the degree of ischemic injury at transplant with biomarkers like neutrophil gelatinase-associated lipocalin or interleukin-18, 19, 27 or assessing the allograft's early response to injury with biomarkers like YKL-40, 34 better capture the biology of peritransplant renal IRI and recovery as it relates to longterm allograft function and longevity.
Study strengths include careful, standardized, and prospective data collection for a relatively large number of recipients at multiple transplant centers with very few losses to follow-up. There are some limitations to consider, however. Despite multivariable adjustment, residual confounding is possible given the observational design. Also, we did not adjust for multiple comparisons in order to identify potential relationships requiring additional study. To evaluate the effects of DGF related to severe allograft IRI at transplant on 12-month outcomes, living-donor kidney transplants were not included. Though 12-month (and subsequently 24-month) follow-up data are now complete, longer-term outcome information is not yet available for the entire cohort.
In conclusion, experimental evidence, as well as clinical data from native kidney settings, suggests the severity and duration of renal IRI affects subsequent function following recovery. DGF is the corollary to this concept in kidney transplantation. With unquestioning acceptance of DGF as dialysis in the first week, however, we run the risk of forgetting that DGF is a (dichotomous) clinical term to describe poor allograft recovery after IRI (which likely varies across a spectrum). Early dialysis may be indicated for reasons unrelated to severe allograft injury (eg, hyperkalemia with surgical fasting), which may not adversely affect long-term allograft function. We noted SCr on POD7 had the strongest association with 12-month eGFR whereas 2 other SCr-based criteria demonstrated clear separation in 12-month eGFR with regard to SGF in the absence of dialysis. However, our data indicate that none of the current definitions for DGF or SGF are ideal, standalone surrogate outcomes in transplantation, though some are probably sufficient in certain situations (eg, as practical endpoints for low-cost pragmatic trials to optimize peritransplant care). Nonetheless, the question remains whether pathophysiologic biomarkers of kidney injury and recovery could improve early prognostic determinations at the individual-patient level and prove useful for therapeutic trials. The transplant community should not grow complacent with a DGF definition that is simply "good enough" for more retrospective analyses.
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